FdaApplication
NDA 214697
Identifiers
- fda_app_no: NDA214697
Properties
| Property | Value |
|---|---|
| applicant_name | ARS PHARMACEUTICALS OPERATIONS INC |
| application_type | NDA |
| approval_date | 2024-08-09 |
Revenue by product
NEFFY
| Period | Revenue |
|---|---|
| Q2 2026 | $26.2M |
| Q1 2026 | $17.5M |
| Q3 2025 | $31.3M |
| Q2 2024 | $0.5M† |
| Q1 2024 | $0.0M† |
| Q4 2023 | $0.0M† |
| Q3 2023 | $0.0M† |
| Q2 2023 | $0.0M† |
| Q1 2023 | $0.0M† |
| Q4 2022 | $0.0M† |
| Q3 2022 | $0.2M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NEFFY | EPINEPHRINE | 1MG/SPRAY | SPRAY;NASAL |
| NEFFY | EPINEPHRINE | 2MG/SPRAY | SPRAY;NASAL |
2 products